Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Severe Extrathoracic Sarcoidosis
NCT03704610Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sarcoidosis comparing INFLIXIMAB with Placebo (2 arms). Primary endpoint: Percentage of patients with remission at 6 weeks. Started Mar 2019; status: completed.
02
Drugs
infliximab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT03704610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704610.